In addition, many other resistance mechanisms have also been identified in ERK-activated tumors such as melanoma, thyroid cancer and colorectal cancer, mostly through the reactivation of MAPK/ERK pathway or bypass activation of PI3K/AKT pathway [37, 38]. This evidence concerns the gene AKT1 and thyroid gland carcinoma.